Taysha Gene Therapies, Inc. Other Current Assets
Taysha Gene Therapies, Inc. (TSHA) had Other Current Assets of $851.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2026-08-11
- 2026-06-30: Other Assets, Current $851.00K.
- 2026-03-31: Other Assets, Current $1.01M.
- 2025-12-31: Other Assets, Current $802.00K.
- 2025-09-30: Other Assets, Current $456.00K.
| Period end | Other Assets, Current | Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $851.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $802.00K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $456.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $657.00K 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $536.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $308.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $465.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $206.00K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $149.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $292.00K 10-K · filed 2025-02-26 | |
| 2023-09-30 | $404.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $510.00K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $532.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $466.00K 10-K · filed 2024-03-19 | $448.00K 10-K · filed 2023-03-28 |
| 2022-09-30 | $380.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $677.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $941.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $863.00K 10-K · filed 2023-03-28 | |
| 2021-09-30 | $1.16M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.01M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $839.00K 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $331.00K 10-K · filed 2022-03-31 | $740.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |